References
- Avet-Loiseau H, Facon T, Daviet A et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res.59, 4546–4550 (1999).
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol.121, 749–757 (2003).
- Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J. Clin.53, 5–26 (2003).
- Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol. Oncol. Clin. North Am.6, 225–247 (1992).
- Brown LM, Gridley G, Pottern LM et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control12, 117–125 (2001).
- Hussein MA, George R, Rybicki L, Karam MA. Skeletal trauma preceding the development of plasma cell dyscrasia: eight case reports and review of the literature. Med. Oncol.20, 349–354 (2003).
- Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.341, 1565–1571 (1999).
- Hussein MA. Thalidomide, age, and future use in multiple myeloma. Blood102, 2-b (2003).
- Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood104, 607–618 (2004).
- Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol.20, 4319–4323 (2002).
- Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol.21, 16–19 (2003).
- Warren NJ, Celgene Corp. Thalomid capsules (thalidomide) prescription product insert. (1998).
- Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol.55, 1827–1834 (1998).
- Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet363, 1802–1811 (2004).
- Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Ann. Rev. Med.53, 629–657 (2002).
- Chen TL, Vogelsang GB, Petty BG et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos.17, 402–405 (1989).
- Raje N, Anderson K. Thalidomide – a revival story. N. Engl. J. Med.341, 1606–1609 (1999).
- Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Med.5, 582–585 (1999).
- Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood82, 3712–3720 (1993).
- Chauhan D, Uchiyama H, Akbarali Y et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood87, 1104–1112 (1996).
- Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood91, 3–21 (1998).
- Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood93, 1658–1667 (1999).
- Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology31, 213–221 (1996).
- Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood93, 3064–3073 (1999).
- Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res.59, 728–733 (1999).
- D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA91, 4082–4085 (1994).
- Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res.64, 971–978 (1997).
- Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia13, 469–472 (1999).
- Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol.87, 503–508 (1994).
- Vacca A, Di LM, Ribatti D et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am. J. Hematol.50, 9–14 (1995).
- Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk. Lymphoma20, 27–38 (1995).
- Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood98, 492–494 (2001).
- Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood80, 887–890 (1992).
- Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med.105, 8–11 (1986).
- Hussein MA, Wood L, Hsi E et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer95, 2160–2168 (2002).
- Rifkin RM. Updated results from a randomized multicenter trial of DVd vs. VAd in patients with newly diagnosed multiple myeloma. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 23).
- Agrawal N. Pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (D) and thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. (2003).
- Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist8(Suppl. 3), 39–45 (2003).
- Srkalovic G, Elson P, Trebisky B, Karam MA, Hussein MA. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol.19, 219–226 (2002).
- Kropff MH, Lang N, Bisping G et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br. J. Haematol.122, 607–616 (2003).
- Moehler TM, Neben K, Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood98, 3846–3848 (2001).
- Mileshkin L, Biagi JJ, Mitchell P et al. Multicenter Phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood102, 69–77 (2003).
- Palumbo A, Bertola A, Falco P et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J.5, 318–324 (2004).
- Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer101, 558–566 (2004).
- Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol.126, 715–721 (2004).
- Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol.35, 969–979 (1996).
- Hussein MA. Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. Oncology (Huntingt)14, 9–15 (2000).
- Baz R, Alemany C, Green R, Hussein MA. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer101, 790–795 (2004).
- Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J. Am. Acad. Dermatol.48, 548–552 (2003).
- Huang SY, Tang JL, Yao M et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann. Hematol.82, 558–564 (2003).
- Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica87, 408–414 (2002).
- Berenson JR, Crowley JJ, Grogan TM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood99, 3163–3168 (2002).
- Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S. T. E. P. S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther.21, 319–330 (1999).
- Neben K, Moehler T, Benner A et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res.8, 3377–3382 (2002).
- Yakoub-Agha I, Attal M, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients – report of the Intergroupe Francophone du Myelome (IFM). Hematol. J.3, 185–192 (2002).
- Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol.121, 768–771 (2003).
- Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol.10, 334–342 (1992).
- Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol.16, 3832–3842 (1998).
Websites
- The Cleveland Clinic: Muliple Myeloma Research Center homepage www.clevelandclinic.org/myeloma (Accessed January 2005).
- International Myeloma Foundation homepage www.myeloma.org (Accessed January 2005).
- Multiple Myeloma Research Foundation: introduction to clinical trials www.multiplemyeloma.org/clinical_trials/index.html (Accessed January 2005).